Onkologie - Kardioprotektion beim Mammakarzinom

Adjuvante und palliative Systemtherapien zählen zur Standardbehandlung des Mammakarzinoms. Allerdings haben einige dieser Therapien ein erhöhtes Risiko für kardiovaskuläre Nebenwirkungen, was insbesondere eine Rolle spielen kann bei älteren Patientinnen mit vorbestehenden kardiovaskulären Erkrankungen oder auch jüngeren Frauen mit kardiovaskulärer Vorbelastung, häufig resultierend aus aggressiven dosisdichten Therapieschemata. Für Therapeuten ist es essentiell, diese kardialen Risiken und Möglichkeiten der Verlaufskontrollen zu verstehen, insbesondere wenn Kombinationstherapien oder verschiedene Substanzen kurz hintereinander appliziert werden.

Literatur

• 01 Thomssen C . AGO fdKMd . AGO-Empfehlungen Mammakarzinom. Diagnostik und Therapie - Update 2008.  Gynäkologie + Geburtshilfe. 2008;  2 38-40
• 02 Hanrahan E O, Gonzalez-Angulo A M, Giordano S H, Rouzier R , Broglio K R, Hortobagyi G N, et al . Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.  J Clin Oncol. 2007;  25 (31) 4952-4960
• 03 Yeh E T, Tong A T, Lenihan D J, Yusuf S W, Swafford J , Champion C , et al . Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.  Circulation. 2004;  109 (25) 3122-3131
• 04 Ewer M S, Lippman S M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.  J Clin Oncol. 2005;  23 (13) 2900-2902
• 05 Ewer M S, Vooletich M T, Durand J B, Woods M L, Davis J R, Valero V , et al . Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.  J Clin Oncol. 2005;  23 (31) 7820-7826
• 06 Hochster H , Wasserheit C , Speyer J . Cardiotoxicity and cardioprotection during chemotherapy.  Curr Opin Oncol. 1995;  7 (4) 304-309
• 07 Swain S M, Whaley F S, Ewer M S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.  Cancer. 2003;  97 (11) 2869-2879
• 08 Dalen EC van , Pal HJ van der , Caron H N, Kremer L C. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2006(4): CD005008. 
• 09 Ryberg M , Nielsen D , Cortese G , Nielsen G , Skovsgaard T , Andersen P K. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.  J Natl Cancer Inst. 2008;  100 (15) 1058-1067
• 10 Minow R A, Benjamin R S, Lee E T, Gottlieb J A. Adriamycin cardiomyopathy--risk factors.  Cancer. 1977;  39 (4) 1397-1402
• 11 Jones S , Holmes F A, O'Shaughnessy J , Blum J L, Vukelja S J, McIntyre K J, et al . Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.  J Clin Oncol. 2009;  27 (8) 1177-1183
• 12 Carver J R, Schuster S J, Glick J H. Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities.  J Clin Oncol. 2008;  26 (19) 3122-3124
• 13 Gardinale D , Sandri M T, Colombo A , Colombo N , Boeri M , Lamantia G , et al . Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.  Circulation. 2004;  109 (22) 2749-2754
• 14 Dalen EC van , Michiels E M, Caron H N, Kremer L C. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2006(4): CD005006. 
• 15 Orditura M , Quaglia F , Morgillo F , Martinelli E , Lieto E , De Rosa G , et al . Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).  Oncol Rep. 2004;  12 (3) 549-556
• 16 Anton A , Ruiz A , Segui M A, Calvo L , Munoz M , Lao J , et al . Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.  Ann Oncol. 2009;  20 (3) 454-459
• 17 Hasinoff B B, Hellmann K , Herman E H, Ferrans V J. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.  Curr Med Chem. 1998;  5 (1) 1-28
• 18 Dalen EC van , Caron H N, Dickinson H O, Kremer L C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005(1): CD003917. 
• 19 Dalen EC van , Caron H N, Dickinson H O, Kremer L C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008(2): CD003917. 
• 20 Swain S M, Wahley F S, Gerber M C, Weisberg S , York M , Spicer D , et al . Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.  J Clin Oncol. 1997;  15 (4) 1318-1332
• 21 Tebbi C K, London W B, Friedman D , Villaluna D , De Alarcon P A, Constine L S, et al . Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.  J Clin Oncol. 2007;  25 (5) 493-500
• 22 Hensley M L, Hagerty K L, Kewalramani T , Green D M, Meropol N J, Wasserman T H, et al . American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.  J Clin Oncol. 2009;  27 (1) 127-145
• 23 Lipshultz S E, Lipsitz S R, Mone S M, Goorin A M, Sallan S E, Sanders S P, et al . Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.  N Engl J Med. 1995;  332 (26) 1738-1743
• 24 Gardinale D , Colombo A , Sandri M T, Lamantia G , Colombo N , Civelli M , et al . Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.  Circulation. 2006;  114 (23) 2474-2481
• 25 Silber J H, Cnaan A , Clark B J, Paridon S M, Chin A J, Rychik J , et al . Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.  J Clin Oncol. 2004;  22 (5) 820-828
• 26 [Anonym]. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators.  N Engl J Med. 1991;  325 (5) 293-302
• 27 Blanco J G, Leisenring W M, Gonzalez-Covarrubias V M, Kawashima T I, Davies S M, Relling M V, et al . Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.  Cancer. 2008;  112 (12) 2789-2795
• 28 Wojnowski L , Kulle B , Schirmer M , Schulter G , Schmidt A , Rosenberger A , et al . NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.  Circulation. 2005;  112 (24) 3754-3762
• 30 Chicco A J, Hydock D S, Schneider C M, Hayward R . Physical activity and survival after diagnosis of invasive breast cancer.  Cancer Epidemiol Biomarkers Prev. 2006;  100 (2) 519-527
• 31 Wonders K Y, Hydock D S, Schneider C M, Hayward R . Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity.  J Appl Physiol. 2008;  7 (3) 147-154
• 32 Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A , McGuire WL  . Acute exercise protects against doxorubicin cardiotoxicity.  Integr Cancer Ther. 1987;  235 (4785) 117-182
• 33 Piccart-Gebhart M J, Procter M , Leyland-Jones B , Goldhirsch A , Untch M , Smith I , et al . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.  Science. 2005;  353 (16) 1659-1672
• 34 Romond E H, Perez E A, Bryant J , Suman V J, Geyer Jr C E, Davidson N E, et al . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.  N Engl J Med. 2005;  353 (16) 1673-1684
• 35 Pritchard K I, Shepherd L E, O'Malley F P, Andrulis I L, Tu D , Bramwell V H, et al . HER2 and responsiveness of breast cancer to adjuvant chemotherapy.  N Engl J Med. 2006;  354 (20) 2103-2111
• 36 Tan-Chiu E , Yothers G , Romond E , Geyer Jr C E, Ewer M , Keefe D , et al . Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.  J Clin Oncol. 2005;  23 (31) 7811-7819
• 37 Seidman A , Hudis C , Pierri M K, Shak S , Paton V , Ashby M , et al . Cardiac dysfunction in the trastuzumab clinical trials experience.  J Clin Oncol. 2002;  20 (5) 1215-1221
• 38 Slamon D J, Leyland-Jones B , Shak S , Fuchs H , Paton V , Bajamonde A , et al . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.  N Engl J Med. 2001;  344 (11) 783-792
• 39 Telli M L, Hunt S A, Carlson R W, Guardino A E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.  J Clin Oncol. 2007;  25 (23) 3525-3533
• 40 Perez E A, Suman V J, Davidson N E, Kaufman P A, Martino S , Dakhil S R, et al . Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.  J Clin Oncol. 2004;  22 (18) 3700-3704
• 41 Garratt A N, Ozcelik C , Birchmeier C . ErbB2 pathways in heart and neural diseases.  Trends Cardiovasc Med. 2003;  13 (2) 80-86
• 42 Negro A , Brar B K, Lee K F. Essential roles of Her2/erbB2 in cardiac development and function.  Recent Prog Horm Res. 2004;  59 1-12
• 43 Crone S A, Zhao Y Y, Fan L , Gu Y , Minamisawa S , Liu Y , et al . ErbB2 is essential in the prevention of dilated cardiomyopathy.  Nat Med. 2002;  8 (5) 459-465
• 44 Grazette L P, Boecker W , Matsui T , Semigran M , Force T L, Hajjar R J, et al . Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.  J Am Coll Cardiol. 2004;  44 (11) 2231-2238
• 45 Suter T M, Cook-Bruns N , Barton C . Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.  Breast. 2004;  13 (3) 173-183
• 46 Guarneri V , Lenihan D J, Valero V , Durand J B, Broglio K , Hess K R, et al . Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.  J Clin Oncol. 2006;  24 (25) 4107-4115
• 47 Schumacher K , Gemke U , Fugunt R , Marmé A , Grischke E , Fehm T . Signifikante Kardiotoxizität unter Trastuzumab- Zwei Case Reports.  Senologie - Zeitschrift fÃŒr Mammadiagnostik und -therapie. 2008;  5 Abstract Nr. A 129
• 48 [Anonym]. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 (8934) 1383-1389
• 49 Hoppe U C, Bohm M , Dietz R , Hanrath P , Kroemer H K, Osterspey A , et al . [Guidelines for therapy of chronic heart failure].  Z Kardiol. 2005;  94 (8) 488-509
• 50 Harris E E, Correa C , Hwang W T, Liao J , Litt H I, Ferrari V A, et al . Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment.  J Clin Oncol. 2006;  24 (25) 4100-4106
• 51 Roychoudhuri R , Robinson D , Putcha V , Cuzick J , Darby S , Moller H  . Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study.  BMC Cancer. 2007;  7 9
• 52 Hooning M J, Botma A , Aleman B M, Baaijens M H, Bartelink H , Klijn J G, et al . Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.  J Natl Cancer Inst. 2007;  95 (5) 365-375
• 53 Harris E E. Cardiac mortality and morbidity after breast cancer treatment.  Cancer Control. 2008;  15 (2) 120-129
• 54 Grey A B, Stapleton J P, Evans M C, Reid I R. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women.  J Clin Endocrinol Metab. 1995;  80 (11) 3191-3195
• 55 Coombes R C, Kilburn L S, Snowdon C E, Paridaens R , Coleman R E, Jones S E, et al . Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.  Lancet. 2007;  369 (9561) 559-570
• 56 Mouridsen H , Keshaviah A , Coates A S, Rabaglio M , Castiglione-Gertsch M , Sun Z , et al . Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.  J Clin Oncol. 2007;  25 (36) 5715-5722
• 57 Lenihan D J, Esteva F J. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer.  Oncologist. 2008;  13 (12) 1224-1234
• 58 Ewer M S, Lenihan D J. Is trastuzumab associated with adverse cardiac effects in patients with breast cancer?.  Nat Clin Pract Oncol. 2008;  5 (4) 192-193
• 59 Jensen B V, Skovsgaard T , Nielsen S L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.  Ann Oncol. 2002;  13 (5) 669-709